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Endothelial nitric oxide synthase (eNOS) deficiency exacerbates proteinuria and renal injury
in several glomerular diseases, but the underlying mechanism is not fully understood. We
recently showed that heparanase is essential for the development of experimental diabetic
nephropathy and glomerulonephritis, and hypothesize that heparanase expression is regu-
lated by eNOS. Here, we demonstrate that induction of adriamycin nephropathy (AN) in
C57BL/6 eNOS-deficient mice leads to an increased glomerular heparanase expression
accompanied with overt proteinuria, which was not observed in the AN-resistant wild type
counterpart. In vitro, the eNOS inhibitor asymmetric dimethylarginine (ADMA) induced
heparanase expression in cultured mouse glomerular endothelial cells. Moreover, ADMA
enhanced transendothelial albumin passage in a heparanase-dependent manner. We con-
clude that eNOS prevents heparanase induction and the development of proteinuria.
Introduction
Proteinuria is a key feature of many glomerular diseases and an independent risk factor for the
progression to renal failure. Proteinuria is caused by damage to the glomerular filtration bar-
rier, which is composed of glomerular endothelial cells covered by a glycocalyx, the glomerular
basement membrane and podocytes. Several studies showed that a reduced glomerular endo-
thelial glycocalyx thickness is associated with the development of proteinuria [1–3]. We
recently showed that endothelial dysfunction and damage precedes podocyte damage in adria-
mycin-induced nephropathy (AN) [4], indicating that a healthy glomerular endothelium is
important to prevent the development of proteinuria and renal damage.
Previous studies showed that a decreased nitric oxide (NO) production and availability con-
tributes to endothelial dysfunction [5]. NO is produced by endothelial cells through endothelial
NO synthase (eNOS). Multiple factors have been suggested to be involved in the regulation of
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eNOS, including reactive oxygen species (ROS), angiotensin II, asymmetric dimethylarginine
(ADMA), protein kinase C (PKC), advanced glycation end products (AGEs), vitamin D and
tumor necrosis factor (TNF)-α [6,7]. eNOS deficiency exacerbates renal injury in accelerated
anti-glomerular basement membrane (GBM) glomerulonephritis [8], experimental focal seg-
mental glomerulosclerosis (FSGS) [9], and diabetic nephropathy (DN) [10]. In addition, eNOS
gene delivery prevented the development of proteinuria in a rat model of FSGS [11]. Recently,
we showed that induction of AN in C57BL/6 mice, an AN resistant strain, with eNOS defi-
ciency induced overt proteinuria, glomerulosclerosis, tubulointerstitial fibrosis and inflamma-
tion [4]. The mechanism how eNOS deficiency exacerbates proteinuria and renal damage
remains unknown.
We previously showed that heparanase, a heparan sulfate (HS) specific endoglycosidase, is
essential for the development of proteinuria and renal damage in experimental DN and
glomerulonephritis [12,13]. In both aforementioned models heparanase-deficient mice dis-
played a preserved glomerular HS expression compared to WT mice. Notably, loss of glomeru-
lar HS expression is associated with the development of proteinuria in most human and
experimental glomerular disease [14]. Heparanase is positively regulated by ROS, angiotensin
II, aldosterone, AGEs, PKC, high glucose and TNF-α [13,15–18], and negatively regulated by
vitamin D [19]. Interestingly, the aforementioned factors that regulate heparanase are also
involved in regulation of eNOS and endothelial function. Importantly, glomerular endothelial
glycocalyx thickness is reduced in diabetic eNOS-deficient mice compared with diabetic wild
type (WT) mice [20]. In addition, heparanase has been shown to impair glycocalyx thickness
[1,3]. Therefore, we hypothesize that heparanase expression is controlled by eNOS.
Materials and Methods
Animals
WT C57BL/6J mice (Monash Animal Services, Monash University, Australia) and eNOS-defi-
cient mice in a C57BL/6J background (Jackson Laboratories, Ben Harbor, ME, USA) were
housed and bred at Monash Animal Services. Animal handling and experiments were
approved by the Monash University Animal Ethics Committee and according to the “Austra-
lian Code of Practice for the Care and Use of Animals for Scientific Purposes”. Balb/c mice
(Harlan, Horst, The Netherlands) were housed at the “Vrije Universiteit Brussel” and animal
experiments were approved by the Animal Care and Use Committee of the “Vrije Universiteit
Brussel”.
Adriamycin-induced nephropathy
AN was induced in 8-week-old C57BL/6J WT and eNOS-deficient mice by an intravenous
injection of 10.5 mg/kg body weight of adriamycin (Sigma-Aldrich, St. Louis, MO, USA), as
described previously [4]. Control mice received an equivalent volume of normal saline (NS).
Mice were sacrificed 14 days after induction of AN. Five mice were used per group.
In Balb/c mice (8 weeks old), AN was induced by an intravenous injection with 10 mg/kg
adriamycin (Pharmacia, Brussels, Belgium) as described [21]. Control mice were injected with
NS. Mice, five-six per time point, were sacrificed 10 and 23 days after induction of AN.
Immunofluorescence staining
Glomerular heparanase and HS expression was determined by indirect immunofluorescence
staining on cryosections (2 μm) as described [22]. Primary antibodies included heparanase
(HPA1, ProsPecTany, Rehovot, Israel) and a mouse monoclonal anti-HS antibody, JM403
Heparanase Regulation by eNOS
PLOSONE | DOI:10.1371/journal.pone.0160894 August 9, 2016 2 / 8
[23]. Secondary antibodies included goat anti-rabbit IgG Alexa 488 and goat anti-mouse IgM
Alexa 488 (Invitrogen Life Technologies, Breda, The Netherlands). Glomerular heparanase and
HS staining intensities were scored in 50 glomeruli per section on a scale between 0 and 10
(0 = no staining, 5 = 50% staining, 10 = 100% staining). Scoring was performed by two inde-
pendent investigators on blinded sections using a Leica CTR6000 microscope.
Cell culture and transendothelial albumin passage
Conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) were cultured as
described previously [24]. Heparanase was stably silenced in mGEnC-1 by transfection of a
heparanase shRNA construct (Qiagen, Venlo, The Netherlands) with Lipofectamine 2000 into
undifferentiated mGEnC-1 and subsequent selection with G418 (Sigma-Aldrich). Differenti-
ated mGEnC-1 were treated with the eNOS inhibitor ADMA (10 μg/ml; Millipore, Amster-
dam, The Netherlands) for 18 hours. For transendothelial albumin passage, differentiated
mGEnC-1 seeded on polyester membranes in tissue culture inserts (0.4 m pore size; Corning
Incorporated, NY, USA) were treated with the eNOS inhibitor ADMA as outlined. Transen-
dothelial albumin passage was determined as described previously [19].
RNA isolation, cDNA generation and real-time PCR
Total RNA was extracted from mouse renal cortex and mGEnC-1 using the RNeasy mini kit
(Qiagen, Venlo, The Netherlands). 1 μg RNA was reverse-transcribed into cDNA using the
RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). Hepara-
nase mRNA expression levels were measured by real-time PCR using gene-specific primers
(Isogen Life Science, de Meern, The Netherlands) and the Fast-start SYBR Green SuperMix
(Roche Diagnostics, Mannheim, Germany), and analyzed with the CFX real-time PCR system
(Bio-Rad Laboratories, Hercules, CA, USA). Used primers: Heparanase, forward 5’-GAGCG
GAGCAAACTCCGAGTGTATC-3’, reverse 5’-GATCCAGAATTTGACCGTTCAGTT -3’, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward 5’-AGAAACCTGCCAAG
TATGATGAC-3’, reverse 5’-TCATTGTCATACCAGGAAATGAG-3’. Heparanase gene
expression levels were quantified with the delta-delta CT method using GAPDH as the house-
keeping gene.
Statistical analysis
Values are expressed as mean ± SEM. Significance was evaluated by a one-way ANOVA and
post hoc analysis with Tukey’s multiple comparison test. A Student’s t-test was used for com-
parison of expression between two different groups. A two-way repeated measures ANOVA
with Bonferroni post-test was used to determine significant differences in transendothelial
albumin passage. Statistical analysis was performed using GraphPad Prism 5.03 (GraphPad
Software, Inc., San Diego, CA, USA). A P-value of  0.05 was considered statistically
significant.
Results
eNOS prevents adriamycin-induced heparanase expression and
proteinuria
To study the in vivo effects of eNOS deficiency on heparanase and HS expression, AN was
induced in C57BL/6 WT, normally an AN resistant strain, and C57BL/6 eNOS-deficient mice.
Fourteen days after the induction of AN, as expected, WT mice failed to develop proteinuria
and had a normal renal function [4]. In contrast, eNOS-deficient mice developed overt
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proteinuria and had an impaired renal function [4]. Cortical heparanase mRNA expression
(Fig 1A) and glomerular heparanase protein expression (Fig 1B and 1D) were normal in WT
ANmice, whereas both heparanase mRNA expression and heparanase protein expression were
significantly increased in the eNOS-deficient AN mice. In addition, glomerular HS expression
was normal in the WT mice, but significantly reduced in the eNOS-deficient mice after induc-
tion of AN (Fig 1C and 1E). To evaluate whether AN caused similar effects on heparanase and
HS expression in AN-sensitive mice as observed in the eNOS-deficient mice, AN was induced
in the AN-sensitive Balb/c mice. We previously showed that eNOS expression was significantly
reduced 24 hours after induction of AN in Balb/c mice [4]. By induction of AN, Balb/c mice
develop proteinuria and renal damage after 10 and 23 days, as described before [21]. Cortical
heparanase mRNA expression (Fig 2A) and glomerular heparanase protein expression (Fig 2B
and 2D) were significantly increased 10 and 23 days after induction of AN, whereas glomerular
Fig 1. eNOS prevents adriamycin-induced heparanase expression and proteinuria. Adriamycin-nephropathy (AN) was
induced in C57BL/6WTmice, an AN resistant strain, and C57BL/6 eNOS-deficient mice. Mice were sacrificed 14 days after the
induction of AN. By induction of AN in WTmice, (A) cortical heparanase mRNA expression, (B,D) glomerular heparanase protein
expression, as determined by immunofluorescence staining, and (C,E) glomerular HS expression, as determined by
immunofluorescence staining, were comparable to control. Cortical heparanase mRNA expression and glomerular heparanase
protein expression were significantly increased in eNOS-deficient mice after induction of AN, whereas glomerular HS expression
was reduced. (D) Representative pictures showing glomerular heparanase protein expression and (E) glomerular HS expression
(magnification x400). 5 mice per group were used for analysis. *P<0.05 and ***P<0.001 versus CTRL. WT, wild type; eNOS KO,
endothelial nitric oxide synthase-deficient; HS, heparan sulfate; CTRL, control; AU, arbitrary units.
doi:10.1371/journal.pone.0160894.g001
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HS expression was significantly reduced (Fig 2C and 2E). Together, these data indicate that
eNOS prevents adriamycin-induced heparanase expression.
The eNOS inhibitor ADMA increases transendothelial albumin passage
in a heparanase-dependent manner
To extend the in vivo findings of eNOS deficiency on glomerular heparanase expression in AN,
we evaluated whether eNOS regulates heparanase expression in glomerular endothelial cells in
vitro. Treatment of mouse glomerular endothelial cells (mGEnC-1) with the eNOS inhibitor
ADMA resulted in a 1.5-fold increased heparanase mRNA expression (Fig 3A). At the func-
tional level, treatment of a monolayer of mGEnC-1 with AMDA increased transendothelial
albumin passage 1.4-fold (Fig 3B). To show that the ADMA-induced increase in transendothe-
lial albumin passage could be possibly mediated by heparanase, heparanase expression in
mGEnC-1 was silenced with shRNA leading to ~60% reduced heparanase mRNA expression.
Upon treatment with ADMA, transendothelial albumin passage was significantly lower in
heparanase-silenced endothelial cells compared with endothelial cells transfected with a
Fig 2. Heparanase expression was increased and HS expression reduced by induction of adriamycin nephropathy
(AN) in AN-sensitive Balb/c mice. AN was induced in Balb/c, which are sensitive for AN-induced renal damage. Mice were
sacrificed 10 and 23 days after the induction of AN. By induction of AN, (A) cortical heparanase mRNA expression and (B,D)
glomerular heparanase protein expression, as determined by immunofluorescence staining, were significantly increased after
10 and 23 days. (C,E) glomerular HS expression was significantly reduced 10 and 23 days after induction of AN, as determined
by immunofluorescence staining. (D) Representative pictures showing glomerular heparanase protein expression and (E)
glomerular HS expression (magnification x400). 5–6 mice were used for analysis. *P<0.05, **P<0.01 and ***P<0.001 versus
CTRL. CTRL, control; AU, arbitrary units.
doi:10.1371/journal.pone.0160894.g002
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scrambled shRNA (Fig 3C). Taken together, these data indicate that eNOS inhibition increased
heparanase expression and thereby transendothelial albumin passage.
Discussion
Our data suggest that eNOS prevents the induction of glomerular heparanase expression and
the development of proteinuria in AN. In addition, inhibition of eNOS activity in cultured
mouse glomerular endothelial cells induces heparanase expression and increases transendothe-
lial albumin passage in a heparanase-dependent manner.
Our study is the first to show that heparanase expression is regulated by eNOS. As outlined,
eNOS and heparanase share regulating factors such as ROS, angiotensin II, PKC, AGEs, vita-
min D and TNF-α [6,7,13,15–17,19]. However, not all of these aforementioned regulating fac-
tors are activators of eNOS and heparanase, nor solely operative in the endothelium, whereas
none of these factors is specific for the glomerular endothelium. Interestingly, vitamin D is a
positive regulator of eNOS, but a negative regulator of heparanase [7,19]. It has also been
described that HS present in the endothelial glycocalyx is important for mechanosensing and
eNOS-mediated NO production [25], which may suggest that a reduced glycocalyx thickness
further hampers NO production, thereby further increasing heparanase expression. This self
amplifying loop will ultimately lead to loss of endothelial glycocalyx and loss of NO produc-
tion, and therefore endothelial dysfunction. We provided clear evidence for the interplay
between eNOS and heparanase in AN, which may be operative in other glomerular diseases as
well, since in the majority of glomerular diseases heparanase expression is increased, whereas
glomerular HS expression is decreased [14]. Nevertheless, additional research is required to
elucidate the complex regulation of both eNOS and heparanase, and their interplay, in glomer-
ular diseases.
The regulation of heparanase expression by eNOS seems important for glomerular diseases,
but may have important implications for other vascular beds outside the kidney as well. The
vascular involvement in clinical manifestations associated with diabetes, sepsis, ischemia,
artherosclerosis, and angiogenesis in cancer [26] may be dictated in part by the interplay
between eNOS and heparanase. Future research should address the beneficial effects of a
Fig 3. Inhibition of eNOS induces heparanase expression and increases transendothelial albumin passage in a heparanase-
dependent manner in culturedmouse glomerular endothelial cells. (A) Treatment of mouse glomerular endothelial cells (mGEnC-
1) with the eNOS inhibitor ADMA for 18 hours resulted in an increased heparanase mRNA expression. (B) Cumulative passage of
FITC-labeled albumin across the mGEnC-1 monolayer (TEER: 28Ω cm2) was increased 1.4-fold compared to control after treatment
with ADMA for 18 hours. (C) Treatment of heparanase-silenced mGEnC-1 with ADMA for 18 hours led to lower transendothelial
albumin passage compared with scrambled mGEnC-1 treated with ADMA. *P<0.05, **P<0.01 and ***P<0.001 versus control.
##P<0.01 versus ADMA scrambled. eNOS; endothelial nitric oxide synthase, ADMA; asymmetric dimethylarginine.
doi:10.1371/journal.pone.0160894.g003
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combined targeting of both eNOS and heparanase in experimental models of the aforemen-
tioned clinical manifestations and glomerular diseases.
Taken together, we postulate that a reduced glomerular expression/activity of eNOS increases
heparanase expression, most likely due to a low NO level. This increased heparanase expression
may explain a reduced thickness of the glomerular endothelial glycocalyx in (experimental) glo-
merular diseases, like diabetic nephropathy and adriamycin nephropathy [2,3].
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